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Themechanisms underpinning integration of instruc-
tions that programnaiveCD8+T cells for effector and/
or memory differentiation are not well understood.
Herein, we demonstrate that interleukin-12 (IL-12)
enhanced and sustained antigen and costimulatory
molecule (B7.1)-induced mTOR kinase activity in
naive CD8+ (OT-I) T cells via phosphoinositide
3-kinase and STAT4 transcription factor pathways.
Blocking mTOR activity by rapamycin reversed
IL-12-induced effector functions because of loss of
persistent expression of the transcription factor
T-bet. Rapamycin treatment of IL-12-conditioned
OT-I cells promoted persistent Eomesodermin
expression and produced memory cell precursors
that demonstrated enhanced sustenance and anti-
gen-recall responses upon adoptive transfer. The
memory cell precursors showed greater tumor effi-
cacy than IL-12-conditioned effector OT-I cells.
These results identify mTOR as the central regulator
of transcriptional programs that determine effector
and/or memory cell fates in CD8+ T cells. Targeting
mTOR activity offers new opportunities to regulate
CD8+ T cell-mediated immunity.
INTRODUCTION
The nature and intensity of instructions received by a naive CD8+
T cell orchestrates gene programs that guide their differentiation
into various functional subsets (Iezzi et al., 1998; Joshi et al.,
2007). The presence of cytokines during antigen stimulation is
instrumental in regulating the transcriptional program of CD8+
T cells for effector and memory functions (Curtsinger et al.,
2003; Xiao et al., 2009). However, the molecular mechanisms
by which integration of cytokine-generated signals determine
antigen- and costimulation-induced T cell responses are not
well defined. Based on the type of cytokine present during
antigen stimulation, naive T cells could give rise to either type I
(interferon-g [IFN-g]), type II (interleukin-4 [IL-4]), type 17 (inter-
leukin-17 [IL-17]), or regulatory (transforming growth factor-b[TGF-b], interleukin-10 [IL-10]) functional outcomes, but the
instructional requirements and the transcriptional regulators for
CD8+ T cells are poorly defined and the understanding is based
on information generated by the use of CD4+ T cells (Bettelli
et al., 2007; Zhou et al., 2009). Besides the ability of effector
CD8+ T cells to protect against variety of challenges, their ability
to produce memory functions is crucial for host immunity.
Emerging insights into CD8+ T cell memory generation demon-
strates the variety of pathways that can give rise to memory cells
(Kaech and Wherry, 2007; Lefranc¸ois and Marzo, 2006). More-
over, the cell type and the pathway used for the emergent
memory cells may impart functional diversity to the memory
CD8+ T cells, thus emphasizing the role played by instructions
early during antigen stimulation for not only effector differentia-
tion but also for memory functions.
Several transcription factors have been shown to coordinate
and regulate the balance between long-lived memory and termi-
nally differentiated effector CD8+ T cells (Intlekofer et al., 2005;
Joshi et al., 2007; Welsh, 2009). The transcription factor T-bet
(Tbx21) is the master regulator of type I effector differentiation
whose expression is considerably enhanced and sustained
in the presence of IL-12 (Joshi et al., 2007; Szabo et al.,
2000). Recent evidence suggests that inflammation-induced
T-bet can control effector and memory fate decisions in CD8+
T cells because increased T-bet expression promotes short-
lived effector cells with a KLRG1hi and IL-7Rlo phenotype,
whereas low T-bet expression promotes long-livedmemory cells
(Joshi et al., 2007). Eomesodermin (Eomes), another T-box con-
taining transcription factor, whose expression increases from the
effector to memory phases of an immune response, is proposed
to promote memory formation (Intlekofer et al., 2005). Moreover,
IL-12 induces T-bet but inhibits Eomesodermin expression to
favor effector versus memory generation (Takemoto et al.,
2006), suggesting the importance of understanding cell-intrinsic
factors that regulate T-bet and Eomesodermin expression
which may enable achieving desirable CD8+ T cell functional
outcomes.
The energy-sensitive kinase mammalian target of rapamycin
(mTOR) has the ability to sense cellular metabolic state (ATP:
AMP), extracellular nutrient availability, presence of growth
factors/cytokines, and control key cellular processes, including
ribosomal genesis, apoptosis/autophagy, proliferation, and cell
growth that govern cell fate (Dennis et al., 2001; Wullschleger
et al., 2006). The immunosuppressive drug rapamycin (specificImmunity 32, 67–78, January 29, 2010 ª2010 Elsevier Inc. 67
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Figure 1. Instructions that Program Naive
CD8+ T Cell for Type I Effector Maturation
Enhances and Sustains mTOR Activity
(A and B) OT-I cells stimulated with BOK (Ag+B7.1)
(±) IL-12 were evaluated for (A) IFN-g by ICS and
(B) cytolytic activity (primary, 72 hr poststimulation;
secondary, 24 hr postsecondary stimulation);
***p < 0.0002.
(C–E) OT-I cells stimulated with antigen (Ag)
(SIINFEKL,10nM)plusB7.1 (100mg/ml) (Ag+B7.1) (±)
IL-12 (2 ng/ml) were evaluated by ICS at the indi-
cated time points for (C) phosphorylated mTOR,
(D) phosphorylated S6K, and (E) phosphorylated
ribosomal S6. For mTOR inhibition, rapamycin
(20 ng/ml) was added 30 min prior to addition of
antigen, cytokine. Data are representative of at
least three independent experiments with similar
outcomes. (Data are presented as mean ± SEM.)
See also Figure S1.
Immunity
mTOR Regulates CD8 Effector/Memory Cell Fateinhibitor of mTOR) is widely used to restrict allograft rejection
reactions (Saunders et al., 2001), and most mechanistic studies
to date have been focused on understanding the action of
rapamycin on CD4+ T cell responses. These studies have
demonstrated that mTOR inhibition by rapamycin induces
CD4+ T cell anergy and/or differentiation into (FoxP3+) regula-
tory T cells (Kang et al., 2008; Zheng et al., 2007). Moreover,
a recent report has implicated the requirement of mTOR kinase
signaling in regulating effector versus regulatory cell lineage
commitment in CD4+ T cells (Delgoffe et al., 2009). Interest-
ingly, recent reports have demonstrated the role of mTOR
in regulating CD8+ T cell trafficking (Sinclair et al., 2008) and
memory differentiation (Araki et al., 2009; Pearce et al.,
2009), but the molecular mechanisms by which mTOR regu-
lates CD8+ T cell differentiation or trafficking remain uncharac-
terized.
In this study, we have identified the role of mTOR in instruc-
tional programming of naive CD8+ T cells for effector and/or
memory fate by regulating expression of T-bet and Eomesoder-
min. Inhibition of mTOR activity blocked persistent T-bet expres-
sion and promoted memory-precursor generation that showed
greater tumor efficacy than type I effector CD8+ T cells. Thus,
our studies suggest a model in which mTOR is a rheostat, which
depending upon the nature and intensity of signals received,
regulates the transcriptional balance to control CD8+ T cell
effector function and/or memory generation.68 Immunity 32, 67–78, January 29, 2010 ª2010 Elsevier Inc.RESULTS
Instructions that Program Naive
CD8+ T Cell for Type I Effector
Differentiation Augment mTOR
Activity
To characterize mechanisms underpin-
ning instructional (signals 1, 2, and
3—antigen [Ag], B7.1 [costimulation], and
IL-12 [cytokine], respectively) program-
ming of naive CD8+ T cells for type I
effector functions, we initiated our studies
to confirm the deterministic role of IL-12in imparting type I effector maturation in OT-I cells stimulated
with adherent cell line, namely BOK expressing H-2Kb, OVAp
(SIINFEKL), and B7.1. As anticipated, addition of IL-12 resulted
in robust IFN-g production and cytotoxic T lymphocyte (CTL)
activity in OT-I cells at 72 hr (Figures 1A and 1B; primary).
Furthermore, when the primary effector OT-I cells (72 hr)
were rested with IL-7 for an additional 72 hr (12% IFN-g detected
at 144 hr) and restimulated with Ag and B7.1 (see Experimental
Procedures), only the IL-12-conditioned OT-I cells reinduced
IFN-g and CTL activity (Figures 1A and 1B; secondary).
Thus, IL-12 has a deterministic role in CD8+ T cell effector
maturation.
Although the kinase mTOR has been implicated as an inte-
grator of various extracellular signals and a sensor for internal
energy levels for determination of cell fate (Hay and Sonenberg,
2004), the role for mTOR in integrating instructions that
program naive CD8+ T cells for type I effector differentiation is
unclear. First, we tested the ability of Ag and B7.1 (Ag+B7.1)
in the presence or absence of IL-12 to activate mTOR in OT-I
cells at various time points after stimulation. Stimulation of
naive OT-I cells with Ag+B7.1 induced mTOR phosphorylation
(activation) by 2 hr, which was maximal at 12 hr and barely
detectable by 48 hr (Figure 1C). Remarkably, IL-12 addition
enhanced Ag+B7.1-induced mTOR phosphorylation at 2 hr,
which was maintained at 48 hr after stimulation (Figure 1C).
Thus, although Ag+B7.1 induces mTOR phosphorylation, the
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Figure 2. IL-12 Enhances Antigen-Induced mTOR Activity via PI3K
and STAT4
(A and B) OT-I cells stimulated with Ag+B7.1 (±) IL-12 and LY294002 (10 mM)
were evaluated by ICS for (A) phosphorylated Akt at 48 hr or (B) phosphory-
lated S6K at the indicated time points.
(C) WT or Stat4/ OT-I cells stimulated with Ag+B7.1 in the presence or
absence of IL-12 were analyzed at the indicated time points for phosphory-
lated S6K; ***p < 0.0001. Experiments shown are representative of three
independent experiments with similar outcomes. (Data are presented as
mean ± SEM.)
Immunity
mTOR Regulates CD8 Effector/Memory Cell Fateaddition of IL-12 enhances and sustains mTOR phosphorylation
in OT-I cells. To verify that the induction of mTOR phosphoryla-
tion also led to its kinase activity, we monitored the kinetics of
p70 S6K phosphorylation (Ser 371), a direct target of mTOR
kinase activity. Although both Ag+B7.1 and Ag+B7.1 plus
IL-12 induced similar amounts of S6K phosphorylation at
12 hr (maximal), the presence of IL-12 was able to sustain the
S6K phosphorylation up to 48 hr (Figure 1D), in correlation
with mTOR phosphorylation (Figure 1C). Similarly, phosphoryla-
tion of S6 (Ser235 and -236), a downstream substrate of S6K,
was also enhanced and sustained in IL-12-conditioned OT-I
cells (Figure 1E). The Ag+B7.1 ± IL-12 stimulation-induced
S6K and S6 phosphorylation in OT-I cells was blocked by rapa-
mycin (specific inhibitor of mTOR complex-1) (Figures 1D and
1E), thus confirming the ability of instructions to activate
mTOR and its kinase activity in OT-I cells. In agreement, with
the reported role for mTOR in regulating cell size (Schmelzle
and Hall, 2000) and the expression of L-type amino acid
transporter (CD98) (Cornish et al., 2006), the induction of blast
transformation and CD98 expression in Ag+B7.1-stimulated
OT-I cells was further augmented by IL-12 in a rapamycin-
sensitive manner (Figure S1A). These observations identify
mTOR as a target of instructions that program CD8+ T cell
effector responses and suggest a potential role for mTOR
kinase in regulating IL-12-determined type I differentiation of
CD8+ T cells.
IL-12-Enhanced mTOR Activity in CD8+ T Cells Requires
PI3K and STAT4
To determine the molecular pathways governing mTOR activity
in CD8+ T cells, we explored whether the Ag-, B7.1-, and
IL-12-induced phosphoinositide 3-kinase (PI3K)-Akt kinase
pathway (Yoo et al., 2002) is required for mTOR signaling
in CD8+ T cells. The OT-I cells stimulated with Ag+B7.1 ±
IL-12 were evaluated for Akt phosphorylation (Thr 308) as
a functional measure of PI3K activity. Although Ag+B7.1
stimulation in the presence or absence of IL-12 induced
similar amounts of Akt phosphorylation by 30 min (data not
shown), the presence of IL-12 augmented Akt phosphorylation
up to 48 hr, which was blocked by the PI3K inhibitor
(LY294002) (Figure 2A), thereby confirming that IL-12 aug-
ments Ag+B7.1-induced PI3K activity in OT-I cells. More-
over, IL-12 augmented mTOR activity (S6K phosphorylation
observed at 2, 12, and 48 hr) was blocked by PI3K inhibition
(Figure 2B), demonstrating that Ag+B7.1 and IL-12-activated
PI3K activity in antigen-stimulated OT-I cells is required for
induction of mTOR kinase activity.
The ability of IL-12 to instruct CD8+ T cells for robust effector
maturation requires STAT4 transcription factor (Jacobson et al.,
1995; Li et al., 2006). To determine whether IL-12 augmented
mTOR activity in OT-I cells is STAT4 dependent, we tested the
ability of wild-type (WT) or Stat4/ OT-I cells to induce S6K
phosphorylation upon stimulation with Ag+B7.1 ± IL-12. In
contrast to our observations with PI3K inhibition, the absence
of STAT4 in OT-I cells did not affect IL-12-induced S6K phos-
phorylation at early time points (2 hr and 12 hr) but failed to main-
tain the induced amounts of S6K phosphorylation (48 hr)
(Figure 2C). Thus, IL-12-induced PI3K and STAT4 have different
roles in regulating mTOR activity in OT-I cells.SustainedmTORActivity Is Essential for Heritable Type I
Effector Functions
Because the presence of IL-12 during antigen stimulation
augments mTOR activity and is deterministic for type I effector
maturation, we hypothesized that sustained mTOR kinase
activity is required for IL-12-programmed type I effector func-
tions in OT-I cells. To test this notion, we stimulated naive OT-I
cells with BOK ± IL-12, and rapamycin and effector functions
were analyzed from the primary and secondary activated OT-I
pool. Addition of rapamycin to IL-12-conditioned OT-I cells did
not affect IFN-g production from primary activated OT-I cells
but reduced their CTL activity associated with decreased
Granzyme B expression (Figures 3A, 3B, and 3C; primary). In
contrast, we noted a complete reversal of IL-12-conditioned
effector functions from the secondary activated pool (IFN-g
production and CTL activity) (Figures 3A and 3B; secondary).
This blockade of IL-12-conditioned type I effector functions
was not because of rapamycin-induced inhibition of cell prolifer-
ation and/or protein synthesis because reactivation of these cells
in the presence of IL-12 resulted in considerable IFN-g produc-
tion (data not shown). These results indicate that IL-12-induced
commitment of naive CD8+ T cells for type I effector functions
requires mTOR activity. In addition, we observed a block inImmunity 32, 67–78, January 29, 2010 ª2010 Elsevier Inc. 69
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Figure 3. Sustained mTOR Activity Is
Essential for Heritable Type I Effector Differ-
entiation of CD8+ T Cells
(A–C) OT-I cells stimulated with Ag+B7.1 (±) IL-12
and rapamycin were evaluated at the primary and
secondary phase for (A) IFN-g by ICS; ***p <
0.0002; n.s., not significant; (B) cytolytic activity;
or (C) granzyme B expression at 72 hr by ICS.
(D and E) OT-I cells were stimulated with Ag+B7.1
(±) IL-12 and rapamycin was added 12 hr after
stimulation to evaluate cells for (D) S6K phosphor-
ylation at 48 hr and (E) IFN-g production at
the primary and secondary phase. Experiments
shown are representative of at least three (A and
B) and two (C–E) independent experiments
with similar outcomes. (Data are presented as
mean ± SEM.) See also Figure S2.
Immunity
mTOR Regulates CD8 Effector/Memory Cell FateIL-12-induced IFN-g production and CTL activity upon rapamy-
cin treatment at 144 hr after primary stimulation (Figure S2A and
B). These results further confirm that rapamycin treatment
blocks type I effector functions, and the loss of effector functions
observed in the secondary activated pool (168 hr) (Figures 3A
and 3B; secondary) is solely because of the inability of these cells
to reinduce IFN-g production and not because of a refractory
state of the rapamycin-treated cells.
To determine whether sustained mTOR activity achieved by
IL-12 treatment was required for type I effector functions, we
blocked persistence of IL-12 induced mTOR activity by adding
rapamycin at 12 hr (mTOR activation peaks at 12 hr; Figures
1C and 1D) (Figure 3D) after Ag+B7.1 stimulation and evaluated
their ability to produce IFN-g production from the primary and
secondary activated OT-I pool. The addition of rapamycin at
12 hr blocked IL-12-induced effector functions, just as observed
with the treatment at 0 hr (Figure 3E; primary activated versus
secondary activated responses). Thus, demonstrating that70 Immunity 32, 67–78, January 29, 2010 ª2010 Elsevier Inc.mTOR activity induced during the first
12 hr is not sufficient to program CD8+
T cells for type I effector function and
emphasizes the requirement of IL-12-
induced persistence of mTOR activity
(12 hr or later) to program type I effector
functions in CD8+ T cells.
IL-12 Augmented mTOR Activity
Is Essential for Sustained T-bet
Expression
Because the sustained expression of
T-bet is necessary and sufficient for
imprinting type I effector cell fate (Mat-
suda et al., 2007) and mTOR inhibition
reversed IL-12 imprinted type I effector
maturation in OT-I cells (Figure 3), we
next sought to determine whether rapa-
mycin treatment affects T-bet expression
in OT-I cells by performing kinetic anal-
ysis of T-bet mRNA expression (Fig-
ure 4A). The addition of IL-12 enhanced
and sustained Ag+B7.1-induced T-betexpression at all time points tested (24–96 hr). However, mTOR
inhibition did not affect Ag+B7.1 plus IL-12-induced early T-bet
expression (24–48h) but blocked IL-12-induced sustained
T-bet mRNA expression (barely detectable by 96 hr), and
correspondingly, the OT-I cells lost T-bet protein expression
(Figure 4B). Moreover, inhibition of mTOR activity at 12 hr was
also able to achieve loss in T-bet expression (Figure S3A), similar
to the observed loss in type I effector maturation (Figure 3E).
Thus, IL-12 augmented (enhanced and sustained) mTOR activity
is required for sustained T-bet expression in CD8+ T cells.
To demonstrate that rapamycin-mediated blockade of IFN-g
production during antigen recall was because of its inability to
reinduce T-bet expression, we rendered IL-12-conditioned
OT-I cells (72 hr type I effector cells) quiescent by IL-7 treatment
for 72 hr (144 hr) and evaluated their T-bet expression before
(144 hr) and after (168 hr) antigen recall. Moderate T-bet
expression was detected in OT-I cells conditioned primarily
with Ag+B7.1 plus IL-12 at 144 hr, which was blocked upon
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Figure 4. IL-12-Enhanced mTOR Phosphorylation Is Essential for T-bet-Determined Type I Effector Maturation of CD8+ T Cells
(A–C) OT-I cells stimulated with Ag+B7.1 (±) IL-12 and rapamycin were evaluated for (A) mRNA for T-bet at the indicated time points by RT-PCR, (B) T-bet protein
expression at the indicated time-points by ICS, and (C) T-bet protein expression by ICS before and after antigen recall. **p < 0.0035; ***p < 0.0005.
(D) WT and Tbx21/ OT-I cells were stimulated with Ag+B7.1 (±) IL-12 and evaluated for IFN-g production at the primary and secondary phase. ***p < 0.0001.
(E and F) OT-I cells stimulatedwith Ag+B7.1 (±) IL-12 and rapamycin were transducedwith T-bet-ER retroviral vector (±) 4-HT (10 nM) and evaluated by ICS for (E)
T-bet protein expression by ICS and (F) IFN-g at secondary phase (168 hr).
(G and H) OT-I cells stimulated with Ag+B7.1 (±) insulin (1 U/ml) and rapamycin were evaluated by ICS for (G) S6K phosphorylation at 48 hr and (H) T-bet expres-
sion at 72 hr. Experiments shown are representative of at least three (A, B, D, E, and F) and two (C, G, and H) independent experiments with similar outcomes.
(Data are presented as mean ± SEM). See also Figure S3.
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mTOR Regulates CD8 Effector/Memory Cell Faterapamycin treatment (Figure 4C). Notably, upon antigen recall,
the IL-12-conditioned OT-I cells reinduced significantly higher
amounts of T-bet protein, which was sensitive to rapamycin
treatment (Figure 4C). These observations demonstrate that
rapamycin treatment blocks persistent T-bet expression, which
may result in the block of IL-12-mediated type I effector matura-
tion. This conclusion was supported by the fact that IL-12
conditioning of Tbx21/ OT-I cells also failed to generate type
I effector functions (Figure 4D, secondary), although their ability
to produce IFN-g in the primary phase was not affected
(Figure 4D, primary). These observations are in agreement withrapamycin-treated IL-12-conditioned OT-I cells (Figure 3A) and
lend further support to our argument that the loss of persistent
T-bet expression upon mTOR inhibition blocks IL-12-condi-
tioned type I effector differentiation in CD8+ T cells.
To directly confirm that the loss of T-bet expression upon
rapamycin treatment led to loss of type I effector functions, we
induced ectopic expression of T-bet in rapamycin-treated
IL-12-conditioned OT-I cells and evaluated their ability to rein-
duce IFN-g production from the secondary activated OT-I
pool. The retroviral vector, T-bet-ER (T-bet-ER RV), was em-
ployedwherein the expression of T-bet is regulated by tamoxifenImmunity 32, 67–78, January 29, 2010 ª2010 Elsevier Inc. 71
Immunity
mTOR Regulates CD8 Effector/Memory Cell Fate(4-HT) (Matsuda et al., 2007). Indeed, addition of tamoxifen (Tm,
10 nM) to T-bet-ER-transduced OT-I cells led to a substantial
increase in T-bet expression (Figure 4E) and restored IFN-g
production in rapamycin-treated IL-12-conditioned OT-I cells
(Figure 4F). Thus, demonstrating that IL-12-induced persistent
mTOR phosphorylation is essential for sustained T-bet expres-
sion and T-bet-dependent type I effector commitment of CD8+
T cells.
The metabolic hormone insulin acts via insulin receptor
substrate (IRS) to activate mTOR kinase (Harris and Lawrence,
2003), whereas 2-deoxyglucose (2-DG), a glycolytic inhibitor,
leads to a blockade of mTOR activity (Dennis et al., 2001). There-
fore, we employed insulin and 2-DG to metabolically regulate
mTOR activity and test whether they could impact T-bet expres-
sion in OT-I cells. Indeed, insulin addition to Ag+B7.1-stimulated
OT-I cells enhanced mTOR activity (S6Kp) and mTOR-depen-
dent increase in T-bet expression (Figures 4G and 4H), whereas
2-DG addition to Ag+B7.1 and IL-12-stimulated OT-I cells led to
loss of mTOR activity and T-bet expression (Figures S3B and
S3C). These results identify mTOR as a critical integrator of
instructions to regulate T-bet expression in CD8+ T cells.
Differential Requirement of mTOR Kinase in CD4+
and CD8+ T Cells
Because treatment of CD4+ T cells with rapamycin induces
anergy and/or deviation to the Foxp3-expressing T regulatory
cells (Delgoffe et al., 2009; Kang et al., 2008; Zheng et al.,
2007), it can be envisaged that inhibition of Ag+B7.1 and
IL-12-induced mTOR activity interferes with CD8+ T cell type I
effector differentiation, because of block in activation, prolifera-
tion, and/or causes deviation to different effector subtypes. In
agreement with the published observations in CD4+ T cells, our
results demonstrate that rapamycin treatment significantly
reduced activation (CD44 expression), proliferation (CFSE dilu-
tion), and cell recovery of CD4+ T cells (OT-II) (Figures S4A and
S4B). However, rapamycin treatment did not affect CD8+ T cell
(OT-I) early (CD69, 12 hr; data not shown) and late activation
(CD44) and only marginally affected proliferation (CFSE) and
cell recovery (Figures S4C and S4D). Moreover, in contrast to
the reported expression of FoxP3 in CD4+ T cells, the rapamy-
cin-treated OT-I cells failed to persistently express FoxP3, which
is required for imparting T cells with regulatory function
(Figure S4E). Furthermore, the loss of T-bet upon mTOR inhibi-
tion did not induce deviation into the type-2 or type-17 subset
(Figures S4F and S4G). These observations were also confirmed
at varying doses of rapamycin (20 ng/ml–2 mg/ml). At higher
doses, rapamycin efficiently blocked mTOR activity in OT-I cells
(S6Kp and S6p), but unlike CD4+ T cells, it failed to block activa-
tion, proliferation, or deviation into regulatory T cell subsets (data
not shown). These results indicate that rapamycin has different
effects on CD4+ and CD8+ T cells, and its ability to block IL-12
induced type I CD8+ effector differentiation is not because of
induction of anergy or deviation to other effector subtypes.
mTOR Inhibition Induces Persistent Eomesodermin
Expression and Produces Memory-Precursor CD8+
T Cells
Because rapamycin treatment blocked type I effector differenti-
ation and failed to induce anergy or expression of other tran-72 Immunity 32, 67–78, January 29, 2010 ª2010 Elsevier Inc.scriptional regulators, we next sought to characterize the fate
of rapamycin-treated IL-12-conditioned OT-I cells. The closely
related transcription factors T-bet and Eomesodermin are
inversely regulated in effector and memory CD8+ T cells (Take-
moto et al., 2006). To determine whether mTOR inhibition, which
curtailed T-bet expression, led to induction of Eomesodermin,
we systematically analyzed Eomesodermin mRNA expression
in OT-I cells. We observed modest Eomesodermin expression
in naive OT-I cells (data not shown), which was enhanced
when stimulated with Ag+B7.1 and reduced upon IL-12 addition
(Figure 5A). However, addition of rapamycin to Ag+B7.1 plus
IL-12-conditioned OT-I cells markedly enhanced Eomesodermin
mRNA expression, which was maintained at all time points
tested (24–96 hr) (Figure 5A). The increase in Eomesodermin
mRNA was confirmed at the protein level because rapamycin-
treated IL-12-conditioned OT-I cells produced significant
increases in Eomesodermin protein (Figure 5B). It is noteworthy
that we consistently observe marginal increases (nonsignificant)
in Eomesodermin protein expression without mRNA induction in
Ag+B7.1 plus IL-12-conditioned OT-I cells (Figures 5A and 5B).
To test whether rapamycin-mediated upregulation of Eomeso-
dermin in OT-I cells is a direct consequence of mTOR inhibition
or a consequence of its ability to inhibit sustained T-bet expres-
sion, we ectopically induced T-bet expression in rapamycin-
conditioned OT-I cells and analyzed for Eomesodermin expres-
sion in the presence or absence of tamoxifen. Indeed, induction
of T-bet in rapamycin-treated OT-I cells decreased Eomesoder-
min expression (Figures 5C). Furthermore, we consistently
observe increased Eomesodermin expression in Tbx21/ OT-I
cells treated with Ag+B7.1 and IL-12 (data not shown). Taken
together, these results demonstrate that mTOR inhibition selec-
tively switches the transcriptional program from sustained T-bet
to Eomesodermin expression in IL-12-conditioned OT-I cells.
Because some studies suggest that type I IFNs (IFN-a and
IFN-b), like IL-12, can also promote type I effector CD8+ T cell
responses (Agarwal et al., 2009), we determined whether IFN-a
could also regulate mTOR activity and T-bet expression in OT-I
cells. As shown in Figures S5A and S5B, IFN-a was unable to
enhance mTOR activity and T-bet expression in Ag+B7.1-stimu-
lated OT-I cells; however, we observed increases in Eomesoder-
min expression and IFN-g production. (Figure S5C and data not
shown). These results confirm that IL-12 has the unique ability to
imprint type I effector maturation by promoting persistent mTOR
and T-bet expression and that IFN-a may lack this activity
because of its inability to promote persistent mTOR activity
and mTOR dependent T-bet expression.
Because Eomesodermin expression has been shown to favor
memory precursor CD8+ T cell generation (Intlekofer et al., 2005),
we next sought to determine whether rapamycin-induced switch
in T-bet to Eomesodermin expression as well as a block in type I
maturation resulted in their transition to memory precursors. We
performed phenotypic analysis of OT-I cells using markers asso-
ciated with memory precursor CD8+ T cells, i.e., CD62L (lymph
node homing) (Wherry et al., 2003), CD69 (lymph node retention)
(Shiow et al., 2006), CD127 (IL-7Ra; essential for memory T cell
maintenance) (Schluns et al., 2000), CD122 (IL-15Rb and essen-
tial for memory CD8+ T cell homeostatic renewal) (Schluns et al.,
2002), KLRG1 (inversely corelated with memory CD8+ T cell
generation) (Joshi et al., 2007), and Bcl-2 (antiapoptotic and
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Figure 5. Inhibition of mTOR Promotes Persistent Eomes Expression and Phenotypic Markers of Memory in CD8+ T Cells
(A and B) OT-I cells stimulated with Ag+B7.1 (±) IL-12 and rapamycin were evaluated for (A) mRNA for Eomes at the indicated time points by RT-PCR and (B)
Eomes protein expression at 72 hr by ICS. *p < 0.03.
(C) OT-I cells stimulated with Ag+B7.1 (±) IL-12 and rapamycin were transduced with T-bet-ER retroviral vector (±) 4-HT (10 nM) and evaluated for Eomes protein
expression at 96 hr.
(D) OT-I cells stimulated with Ag+B7.1 (±) IL-12 and rapamycin were evaluated for CD62L, CD69, KLRG1, CD127, and CD122 expression at 72 hr.
(E) Bcl-2 and Bcl-3 mRNA expression at the indicated time points.
(F and G) OT-I cells stimulated with Ag+B7.1 (±) IL-12 and rapamycin for 72 hr were washed twice and rested for an additional 72 hr in the presence of (F) IL-7
(10 ng/ml), *p < 0.02, and (G) IL-15 (10 ng/ml). *p < 0.02 and percent (%) cell recovery was calculated at 144 hr. Experiments shown are representative of three
independent experiments with similar outcomes. (Data are presented as mean ± SEM.) See also Figure S5.
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mTOR Regulates CD8 Effector/Memory Cell Fateincreased expression in memory T cells) (Grayson et al., 2000).
The IL-12-conditioned OT-I cells treated with rapamycin
expressed markedly higher amounts of CD62L and also demon-
strated persistent CD69 expression in comparison to non-rapa-
mycin-conditioned cells (Figure 5D). The increases in CD62L and
CD69 expression imply that rapamycin-treated OT-I cells could
have greater capacity for lymph node homing and retention.
Moreover, rapamycin-treated cells had a higher frequency
of KLRG1lo cells compared to the non-treated controls, along
with increased and sustained expression of prosurvival genes
(Bcl-2 and Bcl-3) at all time points observed (Figures 5D and
5E). Thus, rapamycin treatment promotes a phenotype indicative
of memory precursor CD8+ T cells. However, rapamycin treat-
ment decreased CD122 expression, and the OT-I cells showeda defect in their ability to respond to IL-15 stimulation in vitro
(Figures 5D and 5F). This is in agreement with the fact that rapa-
mycin treatment causes a loss in T-bet expression and that
CD122 is a direct gene target of T-bet in CD8+ T cells (Matsuda
et al., 2007). Although we did not observe any changes in CD127
expression upon rapamycin treatment, these cells were better
sensitized for IL-7 responsiveness in vitro (Figures 5D and 5G).
Overall, these data indicate that mTOR inhibition imparts
a memory-like phenotype on IL-12-conditioned effector CD8+
T cells along with persistent expression of memory fate tran-
scription factor Eomesodermin.
We next investigated whether the reculture of 72 hr condi-
tioned OT-I cells with IL-7 for an additional 72 hr or antigen recall
(168 hr) affected their memory-like phenotype. As shown inImmunity 32, 67–78, January 29, 2010 ª2010 Elsevier Inc. 73
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Figure 6. Inhibition of mTOR Enhances Memory CD8+ T Cell Generation
OT-I cells (Thy1.1+) stimulated with Ag + B7.1 (±) IL-12 and rapamycin were harvested at 72 hr and adoptively transferred (2 3 106 cells) into BL/6 recipients.
(A) The absolute number of adoptively transferred OT-I cells in the lymph node, **p < 0.0052; spleen, **p < 0.0037; and liver, **p < 0.0012 and **p < 0.0011 at 24 hr
post transfer.
(B–E) The recipient micewere immunizedwith IFA-OVA on day 40 posttransfer and secondary CD8+ T cell responses weremeasured 3 days later (B) The absolute
numbers of adoptively transferred cells before (day 40) and after (day 43) immunization in the spleen. The numbers in parenthesis indicate fold expansion of
CD8a+Thy1.1+ fromday 40 to day 43 and (C) absolute numbers of IFN-g secreting CD8a+Thy1.1+ cells in the spleen on day 43; *p < 0.01, **p < 0.008. The numbers
in parenthesis indicate the MFI of IFN-g expression (D) and Granzyme B expression on CD8a+Thy1.1+ cells in the spleen on day 43 and (E) the in vivo antigen-
specific cytolysis on day 43. A representative of two independent experiments is shown. (Data are presented as mean ± SEM.) See also Figure S6.
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mTOR Regulates CD8 Effector/Memory Cell FateFigures S5D and S5E, rapamycin-treated OT-I cells maintained
their CD62Lhi and KLRG1lo phenotype, but the CD69hi pheno-
type was lost. Notably, the CD122lo phenotype observed at
72 hr was restored and we observed no changes in CD127
expression. Thus, resting the rapamycin-treated OT-I cells with
IL-7 essentially maintained their memory-precursor phenotype,
preventing their ability to maintain the CD69hi phenotype.
Inhibition of mTOR Enhances Memory CD8+ T Cell
Generation
Based on the ability of rapamycin to block IL-12-mediated type I
effector functions, switch persistent T-bet for Eomesodermin
expression, and induce memory-like phenotype in OT-I cells,
we predicted that rapamycin-treated IL-12-conditioned OT-I
cells would produce memory responses after adoptive transfer.
To test this notion, we first investigated if rapamycin treated OT-I
cells show changes in their ability localize within secondary
lymphoid organs as suggested by their increased CD62L and74 Immunity 32, 67–78, January 29, 2010 ª2010 Elsevier Inc.CD69 expression. The adoptively transferred Ag+B7.1 ± IL-12
and rapamycin-conditioned OT-I cells (Thy1.1+) were detected
in C57BL/6 (Thy1.2+) recipients after 24 hr. The rapamycin-
treated OT-I cells demonstrated increased localization in
secondary lymphoid compartments (lymph node and spleen)
and correspondingly lesser numbers were observed in tertiary
sites such as liver (Figure 6A) and blood (Figure S6A). The non-
rapamycin-treated OT-I cells did not show this pattern of locali-
zation (Figure 6A). However, we did not observe any significant
differences in the frequency of cells in the lung (Figure S6A).
Thus, a block in mTOR activity shifts the localization of antigen
plus IL-12-conditioned CD8+ T cells to the secondary lymphoid
compartment.
To confirm whether rapamycin treatment that produces
memory precursor OT-I cells enables them for memory func-
tions, we evaluated the persistence of the adoptively transferred
cells (day 40) and tested their antigen recall response (day 43).
The OT-I cells conditioned with Ag+B7.1 plus IL-12 demonstrate
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Figure 7. mTOR Inhibition Promotes CD8+ T
Cell-Mediated Antitumor Immunity
(A and B) Naive or 72 hr conditioned OT-I cells
were adoptively transferred into BL/6 recipients.
Mice were inoculated with 2 3 106 E.G7 tumor
cells 24 hr postadoptive transfer of OT-I cells. (A)
Tumor size (mm3) over time from tumor inoculation
and (B) percent of tumor-free survival over time
from tumor inoculation is shown. A representative
of two independent experiments is shown.
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mTOR Regulates CD8 Effector/Memory Cell Fategreater persistence than Ag+B7.1-stimulated OT-I cells
(Figure 6B). However, rapamycin treatment markedly enhanced
the ability of OT-I cells to persist, as demonstrated by the
increased numbers detected on day 40 (Figure 6B). The
increased persistence of OT-I cells was largely because of their
differential ability to survive rather than undergo greater homeo-
static proliferation, as rapamycin-treated OT-I cells show iden-
tical CFSE dilution as the nontreated controls (Figures S6B and
S6C) but have higher expression of survival-associated gene
expressions (Figure 5E). Moreover, the rapamycin-treated OT-I
cells produced vigorous antigen recall responses as assessed
by clonal expansion upon antigen rechallenge (Figure 6B) and
effector responses: IFN-g, Granzyme B expression, and CTL
activity (Figures 6C, 6D, and 6E). More importantly, there is
increased expression of IFN-g and Granzyme B on a per-cell
basis in the rapamycin-treated group, which indicates that the
increases in vivo cytolytic killing observed in this group is not
only because of increased cell numbers, but also because of
increased effector maturation upon antigen-recall. Therefore,
rapamycin treatment not only enhances CD8+ T cell persistence,
but also empowers them for greater effector capacities upon
antigenic rechallenge. Careful phenotypic analysis of the adop-
tively transferred OT-I cells at early (day 5) and late (day 40;
memory) time points show that rapamycin-treated cells have
higher CD127, CD62L, and CD69 expression on day 5, maintain-
ing their memory precursor phenotype (Figure S6D), but this
phenotype was altered at day 40 posttransfer (Figure S6E). In
addition, no changes in T-bet and CD122 expression were
noted on day 40 (Figure S6F). Collectively, these observations
demonstrate that rapamycin treatment promotes CD8+ T cell
memory precursor generation that can localize within the
secondary compartments and persist upon adoptive transfer.
However, they alter their phenotype over time and produce
robust antigen-recall effector responses.Rapamycin-Treated IL-12-Conditioned OT-I Cells
Demonstrate Augmented Tumor Efficacy
The use of ex vivo generated tumor-antigen-specific effector
CD8+ T cells in adoptive cell transfer (ACT) has produced tumor
regressions in the clinical setting (Morgan et al., 2006). To test
the tumor efficacy of rapamycin-treated IL-12-conditioned
OT-I cells, we adoptively transferred IL-12-conditioned OT-I
cells (72 hr) that were either treated with or without rapamycin
into intact C57BL/6 recipients bearing E.G7 tumor cells and
their tumor size (s.c.), and survival was monitored over time.
In comparison to naive OT-I cell recipients, the mice receiv-
ing Ag+B7.1-stimulated OT-I cells showed marginal benefits
(100% to 80% fatality by day 30), which was further enhancedby the IL-12-conditioned OT-I cells (50% fatality by day 30).
Rapamycin-treated IL-12-conditioned OT-I cells showed mark-
edly enhanced tumor efficacy as more than 78% of the recipient
animals survived tumor-free till day 120 (Figure 7B). Moreover,
the rapamycin-treated IL-12-conditioned OT-I cells also show
markedly enhanced control of tumor size when compared to
non-rapamycin-treated counterparts (Figure 7A). These results
demonstrate that inhibition of mTOR programs antigen and
IL-12-conditioned CD8+ T cells for memory responses that
show greater tumor efficacy than IL-12-conditioned effector
CD8+ T cells.DISCUSSION
Durable immunity requires CD8+ T cells to demonstrate both
effector as well as memory functions. Instructions received by
a naive CD8+ T cell imprint differentiation into short-lived
effectors and/or long-lived memory fates by regulating gene
programs governed by master transcriptional factors (Kaech
and Wherry, 2007). Many elegant studies have successfully
elucidated the requirements for three distinct instructions,
namely, MHC class I-antigen, costimulatory molecules, and
cytokine, to achieve full activation and differentiation of naive
CD8+ T cells (Curtsinger et al., 2003), but the mechanism by
which they are integrated to regulate transcriptional programs
for CD8+ T cell functional differentiation is not entirely clear.
Because cellular energy status and the energy-sensitive kinase
mTOR have been implicated in T cell activation and anergy
and survival (Araki et al., 2009; Cham and Gajewski, 2005;
Delgoffe et al., 2009; Pearce et al., 2009), we predicted that
the mTOR kinase activity is instrumental to the integration of
instructions that program differentiation of CD8+ T cells. In this
report, we demonstrate that Ag+B7.1 and IL-12 require the
PI3K and STAT4 signaling pathways to augment mTOR activity,
which determines effector and memory functional outcomes in
CD8+ T cells by regulating T-bet and Eomesodermin expression.
Recent reports have demonstrated a role for mTOR activity in
memory CD8+ T cell differentiation (Araki et al., 2009; Pearce
et al., 2009). However, the mechanisms by which mTOR inte-
grates extracellular instructions and regulates gene programs
to achieve distinct functional fates in CD8+ T cells is unknown.
By stimulating naive CD8+ T cells with defined quantity and
quality of instructions, we have established that IL-12 provides
the deterministic signal for CD8+ effector maturation by
enhancing and maintaining mTOR activity. Moreover, the strin-
gent requirement for IL-12-induced STAT4 activity for CD8
type I effector functions is in large part because of its ability
to maintain mTOR activity, which in turn produces persistentImmunity 32, 67–78, January 29, 2010 ª2010 Elsevier Inc. 75
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mTOR Regulates CD8 Effector/Memory Cell FateT-bet expression. Although at this juncture we do not fully under-
stand how STAT4 maintains mTOR activity, it can be reasoned
that STAT4 sustains transcription of mTOR. Moreover, the ability
of mTOR to sustain T-bet expression (mRNA and protein) is
intriguing and deserves further studies. Nevertheless, by identi-
fying the pathways by which instructions regulate mTOR activity
for T-bet-mediated functional maturation, we have generated
new opportunities to modulate CD8+ T cell responses for desir-
able outcomes.
The selective ability of rapamycin to inhibit IFN-g production in
the secondary (144 hr and 168 hr), but not the primary (72 hr),
phase of antigen stimulation was perplexing, but it’s interesting
to note that rapamycin treatment did not affect the expression
of homeobox transcription factor Hlx (data not shown), which
has been shown to regulate IFN-g production in the primary
phase (Mullen et al., 2002). Therefore, the selective blockade of
secondary IFN-g production, but not primary, upon rapamycin
treatment is because of its ability to block persistent T-bet
expression. This is consistent with the observation that primary
IFN-g production is not perturbed in Tbx21/ OT-I T cells (this
report) and with IFN-a being able to promote primary IFN-g
production in OT-I cells without promoting sustained T-bet
expression, indicates the role played by factors other than
T-bet in regulating primary IFN-g production in CD8+ T cells.
Indeed, our ability to restore antigen recall IFN-g expression by
ectopic T-bet expression confirms the causal role of T-bet defi-
ciency in rapamycin-mediated loss of heritable effector func-
tions. Although the mechanisms by which mTOR inhibition
curtails IL-12 sustained T-bet expression is not readily apparent,
it is not because of rapamycin-induced inhibition of protein trans-
lation as expression of several proteins like Eomesodermin and
CD62L are enhanced upon rapamycin treatment. It is possible
that mTOR, which has been shown to tether several transcrip-
tional factors (both activators and repressors) (Wullschleger
et al., 2006) may regulate T-bet expression based on its activity.
The balance between transcriptional factors T-bet and Eome-
sodermin has been shown to determine effector andmemory cell
fate in CD8+ T cells (Intlekofer et al., 2005). The fact that ectopic
expression of T-bet prevented increased Eomesodermin
expression in rapamycin-treated OT-I cells and that Tbx21/
OT-I cells showed higher Eomesodermin expression, indicates
that rapamycin-mediated upregulation of Eomesodermin is
because of its ability to block persistent T-bet expression.
Notably, we did not observe any changes in Eomesodermin
expression in Ag+B7.1 ± IL-12 and rapamycin-conditioned
Stat4/OT-I cells, suggesting that regulation of Eomesodermin
by IL-12 and rapamycin in CD8+ T cells is STAT4 independent
(data not shown). The ability to instructionally modulate the level
of mTOR activity for relative expression of T-bet and Eomeso-
dermin offers new means to target transcriptional programs in
CD8+ T cells.
The treatment of antigen plus IL-12-conditioned OT-I cells
with rapamycin induced changes in phenotypic markers repre-
senting memory precursors (72 hr, 144 hr, and day 5). However,
these changes were transient because by day 40, the phenotype
was similar to nontreated controls. These observations and the
recent report (Araki et al., 2009) suggests that continuous pres-
ence of rapamycin may be required to maintain the memory-like
phenotype to day 40. Evidently, the in vitro rapamycin treated76 Immunity 32, 67–78, January 29, 2010 ª2010 Elsevier Inc.OT-I cells upon adoptive transfer undergo homeostatic prolifer-
ation in the absence of rapamycin, which may permit restoration
of phenotype and functions. Exploring the notion that the extent
of rapamycin exposure may affect effector versus memory
functional maturation is provocative because it is likely to identify
new strategies to generate functionally distinct types of memory
CD8+ T cells with heterogeneous efficacy against tumor and/or
infectious challenges.
Strikingly, the in vitro rapamycin-generated memory-
precursor OT-I cells were more effective at promoting tumor
immunity than IL-12-conditioned type I effector OT-I cells after
adoptive transfer. The enhanced efficacy could be ascribed to
several changes noted in their phenotype, localization, greater
survival because Bcl-2-related gene expression, and robust
effector functions upon antigen rechallenge. Although it would
be interesting and challenging to delineate the relative contribu-
tions of all the changes produced by rapamycin treatment, the
reported findings represent an important first step toward iden-
tifying the use of rapamycin to generate durable tumor immunity.
The recent reports showing the ability of stem cell like or central
memory CD8+ T cells to have greater tumor efficacy (Gattinoni
et al., 2009) supports the paradigm that memory CD8+ T cells
rather than effector CD8+ T cells enable greater tumor immunity.
In summary, we have identified mTOR as an important medi-
ator of instructionally programmed CD8+ effector and memory
cell fate by demonstrating its ability to regulate T-bet and Eome-
sodermin expression. The information offers new targets to
modulate CD8 T cell responses in infectious diseases, tumors,
autoimmunity, and/or graft-versus-host disease.
EXPERIMENTAL PROCEDURES
Mice and Reagents
The C57BL/6, CD4+ TCR transgenic Rag2/ (OT-II), CD8+ TCR transgenic
Rag2/ (OT-I, WT), Stat4/ OT-I Rag2/, and Tbx21/ OT-I Rag2/
mice were bred, housed, and used according to IACUC guidelines at RPCI.
The rmIL-12 (2 ng/ml) was a gift from Wyeth, Inc. (Cambridge, MA). IFN-a
was a gift from T. Tomasi (RPCI). rmIL-7 was purchased from Peprotech
(Rocky Hill, NJ). 2-DG, 4-HT, and rapamycin were purchased from Sigma
Aldrich (St. Louis, MO). LY290042 was purchased from Calbiochem. Insulin
was purchased from Novo Nordisk Inc. (Princeton, NJ).
Stimulation of OT-I Cells
Naive OT-I cells were stimulated with latex microspheres expressing H-2Kb/
SIINFEKL and B7.1 as described previously (Goldberg et al., 2003). Naive
OT-II cells were stimulated with anti-CD3-/anti-CD28-coated latex beads. In
some experiments, the cell line derived from embryonic fibroblasts, namely,
BOK (MEC.B7.SigOVA: expressing H-2Kb, OVAp [SIINFEKL], and B7.1),
were used as antigen-presenting cells to stimulate naive OT-I cells as previ-
ously described (Li et al., 2006).
Evaluation of Secondary Antigen-Recall Responses In Vitro
For studying secondary antigen-recall response in vitro; OT-I cells harvested at
72 hr (primary) were washed thrice with medium and recultured (13 105/ml) for
an additional 72 hr in a 24-well plate with IL-7 (10 ng/ml) only. At 144 hr, the
cells were harvested, washed thrice with medium, had numbers adjusted
(5 3 105), and were restimulated with Ag/B7.1 only for an additional 24 hr
(secondary stimulation). At 168 hr, the cells recovered were evaluated by
flow cytometry and in vitro functional assay.
Retroviral Transduction and T-Bet Induction
T-bet-ER RV was cotransfected into Platinum-E cells together with the retro-
viral packaging vector pCL-Eco using LipoD293 DNA in vitro transfection
Immunity
mTOR Regulates CD8 Effector/Memory Cell Fatereagent (SignaGen Laboratories) following the manufacturer’s instructions.
The medium was replaced the following day, and retroviral supernatant was
collected 3 days after transfection. For transduction, naive OT-I cells stimu-
lated for 24 hr, were suspended in retroviral supernatant containing polybrene
(8 mg/ml; Sigma-Aldrich), and were spin-transduced at 2200 rpm for 90 min at
30C. After spin-transduction, cells were cultured in fresh medium containing
the same polarizingmilieu as before, along with the addition of 4-HT (10 nM). At
the end of 72 hr after initial stimulation, cells were washed thrice and main-
tained in the absence of any stimulation but in the presence of 4-HT and
IL-7 (10 ng/ml).
Statistical Analysis
For statistical analysis, the unpaired Student’s t test was applied. Tumor
survival between various groups was compared using Kaplan Meier survival
curves and log-rank statistics. Significance was set at p < 0.05.
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